CN105535051A - Pharmaceutical preparation for preventing and treating toxoplasmosis of pigs and preparation method of pharmaceutical preparation - Google Patents
Pharmaceutical preparation for preventing and treating toxoplasmosis of pigs and preparation method of pharmaceutical preparation Download PDFInfo
- Publication number
- CN105535051A CN105535051A CN201610117167.5A CN201610117167A CN105535051A CN 105535051 A CN105535051 A CN 105535051A CN 201610117167 A CN201610117167 A CN 201610117167A CN 105535051 A CN105535051 A CN 105535051A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical preparation
- sodium
- preparation
- takes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 42
- 201000005485 toxoplasmosis Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 241000282887 Suidae Species 0.000 title abstract description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 33
- 239000011734 sodium Substances 0.000 claims abstract description 33
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 claims abstract description 21
- 229960004082 DOXYCYCLINE HYDROCHLORIDE Drugs 0.000 claims abstract description 21
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 18
- 241000018646 Pinus brutia Species 0.000 claims abstract description 18
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 18
- 229960001031 Glucose Drugs 0.000 claims abstract description 17
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 43
- 241000282898 Sus scrofa Species 0.000 claims description 42
- 239000000843 powder Substances 0.000 claims description 17
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 16
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 16
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 16
- -1 trimethoxy pyrimidine sodium Chemical compound 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 12
- 229940079593 drugs Drugs 0.000 abstract description 8
- 210000003734 Kidney Anatomy 0.000 abstract description 6
- 210000004185 Liver Anatomy 0.000 abstract description 4
- 230000000844 anti-bacterial Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 206010037660 Pyrexia Diseases 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 231100000486 side effect Toxicity 0.000 abstract description 3
- DQDZQHMCPDUUPC-UHFFFAOYSA-N Sulfadimethoxine sodium Chemical compound [Na+].COC1=NC(OC)=CC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 DQDZQHMCPDUUPC-UHFFFAOYSA-N 0.000 abstract 2
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 240000003743 Bupleurum rotundifolium Species 0.000 abstract 1
- 210000000936 Intestines Anatomy 0.000 abstract 1
- 229960000703 Sulfadimethoxine Sodium Drugs 0.000 abstract 1
- 241001619454 Wolfiporia Species 0.000 abstract 1
- 150000003045 fructo oligosaccharides Chemical class 0.000 abstract 1
- 235000012054 meals Nutrition 0.000 abstract 1
- 239000004575 stone Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 8
- 241000223996 Toxoplasma Species 0.000 description 6
- 230000000968 intestinal Effects 0.000 description 6
- 230000002633 protecting Effects 0.000 description 6
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 229960001663 sulfanilamide Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 2
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 2
- 206010025482 Malaise Diseases 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 244000052616 bacterial pathogens Species 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 2
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 229940026752 topical Sulfonamides Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 230000001228 trophic Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 229960001092 OTHER ANTIBACTERIALS in ATC Drugs 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 206010048282 Zoonosis Diseases 0.000 description 1
- 208000003558 Zoonosis Diseases 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001932 seasonal Effects 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Abstract
The invention discloses a pharmaceutical preparation for preventing and treating toxoplasmosis of pigs. The pharmaceutical preparation comprises following components in parts by weight through compatibility: 8-20 parts of doxycycline hydrochloride, 10-20 parts of sulfamonomethoxine sodium or sufisomezole, 1-4 parts of sulfatrimethoxine sodium or sulfadimethoxine sodium, 3-6 parts of fructooligosaccharides, 20-40 parts of anhydrous glucose, 20-30 parts of medical stone, 5-10 parts of Chinese thorowax roots, 4-10 parts of Wolfiporia extensa and 5-10 parts of pine needle meal. The invention further discloses a preparation method of the pharmaceutical preparation. According to mutual compatibility of the components of the pharmaceutical preparation, medicine absorption is promoted, the effects of the medicines are enhanced, toxic and side effects are reduced, and meanwhile, the preparation has the functions of protection of the liver and the kidney, antibacterial performance, abatement of fever, promotion of growth of normal flora in intestines and enhancement of the body immunity functions.
Description
Technical field
The present invention relates to the technical field of veterinary drug preparation, refer in particular to a kind of pharmaceutical preparation preventing and treating swine toxoplasmosis, and relevant with its preparation method.
Background technology
Swine toxoplasmosis, is also called tokoplasmosis or toxoplasmosis, is the protozoacide being caused infecting both domestic animals and human by Toxoplasmosis animal and human.Primary disease with high heat, to breathe and the miscarriage of neurological symptom, animal dead and pregnant animal, stillborn fetus, fetal anomaly is for principal character.Toxoplasmosis is that a kind of parasitic protozoa of universal Zoonosis is sick, extensively exists in domestic animal and wild animal.Toxoplasma is a kind of many hosts protozoon, not tight to the selection of intermediate host, there will be a known 200 many animals, comprises mammal, birds and the mankind etc. and all can be used as intermediate host.Primary disease be mainly in 3 ~ 4 the monthly age pig; Though without obviously seasonal, also not climate restriction, hot season autumn in summer of some place 6 ~ JIUYUE is multiple.Fulminant type, acute can be divided into according to popular form, sporadicly distribute and inapparent infection.Primary disease fulminant type is within a short time, and can make most of live pig morbidity on whole pig farm, mortality rate can reach more than 60%, causes serious economic loss to pig industry.Infect this after being ill, the immunity degradation of pig, other antibacterials of easy secondary or viral disease, toxoplasma is only responsive to sulfonamides, and to other antibiotic ineffective, and one of them serious side effect of sulfonamides is toxic to kidney, affect the excretion of infected animal, cause that sb.'s illness took a turn for the worse further.In addition, it is absolutely useless that infected animal understands appetite usually, and after from infecting to curing, recovery has a strong impact on the growth promoter of animal during this period of time, causes weight loss serious, increase aquaculture cost further.
Summary of the invention
For solving the problem, the object of the present invention is to provide a kind of pharmaceutical preparation of novel control swine toxoplasmosis, the mutual compatibility of each component in this formula, promote drug absorption, strengthen its effect, reduce toxic and side effects, have to protect the liver simultaneously and protect kidney, the antibacterial growth of bringing down a fever, promoting enteral normal flora, the effect of enhancing human body immunity function.
The present invention also aims to the preparation method of the pharmaceutical preparation that a kind of novel control swine toxoplasmosis is provided.
For reaching above-mentioned purpose, solution of the present invention is:
A kind of pharmaceutical preparation of novel control swine toxoplasmosis, formulated by weight by following compatibility: doxycycline hydrochloride 8-20 part, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole 10-20 part, trimethoxy pyrimidine sodium or SDM sodium 1-4 part, oligofructose 3-6 part, anhydrous glucose 20-40 part, Maifanitum 20-30 part, Radix Bupleuri 5-10 part, Poria 4-10 part, pine needle powder 5-10 part.Wherein, pine needle powder is the Folium Pini dried at dry place, pulverizes 80 mesh sieves, below water content 3wt%.
A preparation method for the pharmaceutical preparation of novel control swine toxoplasmosis, comprises the following steps:
Step one, takes Maifanitum, Radix Bupleuri, Poria, pine needle powder, micronizing, crosses 150 mesh sieves, makes pharmaceutical carrier;
Step 2, takes doxycycline hydrochloride, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole, trimethoxy pyrimidine sodium or SDM sodium, oligofructose, abundant mix homogeneously;
Step 3, by the mixture of step one and the abundant mix homogeneously of the mixture of step 2;
Step 4, takes anhydrous glucose, stirs, obtain pharmaceutical preparation of the present invention together with step 3 gained mixture.
After adopting such scheme, the pharmaceutical preparation of a kind of novel control swine toxoplasmosis of the present invention is made up of Western medicine component and carrier component, wherein, western medicine composition is broad spectrum antibiotic, cooperatively interact, its effect strengthens more than several times, have very strong antibacterial, sterilize, kill the effects such as toxoplasma; Vehicle component has heat-clearing and toxic substances removing; bring down a fever, adsorb pathogenic bacterium in intestinal and toxin; protection intestinal mucosa; for intestinal beneficial microbes flora provides trophic factors, safeguards the ecological balance of intestinal beneficial flora; regulate gastrointestinal function, improve anti-stress ability, strengthen immunologic function, protect the liver effects such as protecting kidney.Therefore, compared with prior art, have the following advantages:
One, there is complementary action in carrier of the present invention and the mutual compatibility of Western medicine, have efficient, quick-acting, safeguard the effect such as enteral microecological balance, enhancing human body immunity power;
Two, the western medicine composition of employing, has the effect of very strong antibacterial, the toxoplasma etc. that sterilizes, kills;
Three, the vehicle component of employing, the pathogenic bacterium in absorption intestinal and toxin, protection intestinal mucosa, for intestinal beneficial microbes flora provides trophic factors, safeguards the ecological balance of intestinal beneficial flora, improves anti-stress ability;
Four, can protect the liver and protect kidney, reduce the kidney toxic and side effects that western medicine composition causes, safe and reliable;
Five, remarkable to the prevention effect of swine toxoplasmosis;
Meanwhile, a kind of preparation method of pharmaceutical preparation of novel control swine toxoplasmosis is easy, easily applies.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in further detail.
Embodiment one
A pharmaceutical preparation for novel control swine toxoplasmosis, formulated by weight by following compatibility: 1 part, doxycycline hydrochloride 8 parts, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole 10 parts, trimethoxy pyrimidine sodium or SDM sodium, oligofructose 3 parts, anhydrous glucose 20 parts, Maifanitum 20 parts, Radix Bupleuri 5 parts, 4 parts, Poria, pine needle powder 5 parts.
A preparation method for the pharmaceutical preparation of novel control swine toxoplasmosis, comprises the following steps:
Step one, takes Maifanitum, Radix Bupleuri, Poria, pine needle powder, micronizing, crosses 150 mesh sieves, makes pharmaceutical carrier;
Step 2, takes doxycycline hydrochloride, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole, trimethoxy pyrimidine sodium or SDM sodium, oligofructose, abundant mix homogeneously;
Step 3, by the mixture of step one and the abundant mix homogeneously of the mixture of step 2;
Step 4, takes anhydrous glucose, stirs, obtain pharmaceutical preparation of the present invention together with step 3 gained mixture.
Embodiment two
A pharmaceutical preparation for novel control swine toxoplasmosis, formulated by weight by following compatibility: doxycycline hydrochloride 8 parts, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole 10 parts, trimethoxy pyrimidine sodium or SDM sodium 1-4 part, oligofructose 3 parts, anhydrous glucose 40 parts, Maifanitum 30 parts, Radix Bupleuri 10 parts, 10 parts, Poria, pine needle powder 10 parts.
A preparation method for the pharmaceutical preparation of novel control swine toxoplasmosis, comprises the following steps:
Step one, takes Maifanitum, Radix Bupleuri, Poria, pine needle powder, micronizing, crosses 150 mesh sieves, makes pharmaceutical carrier;
Step 2, takes doxycycline hydrochloride, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole, trimethoxy pyrimidine sodium or SDM sodium, oligofructose, abundant mix homogeneously;
Step 3, by the mixture of step one and the abundant mix homogeneously of the mixture of step 2;
Step 4, takes anhydrous glucose, and being mixed with step 3 gained stirs, and obtains pharmaceutical preparation of the present invention.
Embodiment three
A pharmaceutical preparation for novel control swine toxoplasmosis, formulated by weight by following compatibility: 4 parts, doxycycline hydrochloride 20 parts, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole 20 parts, trimethoxy pyrimidine sodium or SDM sodium, oligofructose 3 parts, anhydrous glucose 30 parts, Maifanitum 25 parts, Radix Bupleuri 8 parts, 8 parts, Poria, pine needle powder 10 parts.
A preparation method for the pharmaceutical preparation of novel control swine toxoplasmosis, comprises the following steps:
Step one, takes Maifanitum, Radix Bupleuri, Poria, pine needle powder, micronizing, crosses 150 mesh sieves, makes pharmaceutical carrier;
Step 2, takes doxycycline hydrochloride, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole, trimethoxy pyrimidine sodium or SDM sodium, oligofructose, abundant mix homogeneously;
Step 3, by the mixture of step one and the abundant mix homogeneously of the mixture of step 2;
Step 4, takes anhydrous glucose, and being mixed with step 3 gained stirs, and obtains pharmaceutical preparation of the present invention.
Embodiment four
A kind of pharmaceutical preparation of novel control swine toxoplasmosis, formulated by weight by following compatibility: doxycycline hydrochloride 16 parts, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole 15 parts, trimethoxy pyrimidine sodium or 2 parts, SDM sodium, oligofructose 4 parts, anhydrous glucose 30 parts, Maifanitum 30 parts, Radix Bupleuri 10 parts, 10 parts, Poria, pine needle powder 10 parts.
A preparation method for the pharmaceutical preparation of novel control swine toxoplasmosis, comprises the following steps:
Step one, takes Maifanitum, Radix Bupleuri, Poria, pine needle powder, micronizing, crosses 150 mesh sieves, makes pharmaceutical carrier;
Step 2, takes doxycycline hydrochloride, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole, trimethoxy pyrimidine sodium or SDM sodium, oligofructose, abundant mix homogeneously;
Step 3, by the abundant mix homogeneously of mixture of the mixture step 2 of step one;
Step 4, takes anhydrous glucose, stirs, obtain pharmaceutical preparation of the present invention together with step 3 gained mixture.
Embodiment five
A kind of pharmaceutical preparation of novel control swine toxoplasmosis, formulated by weight by following compatibility: doxycycline hydrochloride 20 parts, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole 15 parts, trimethoxy pyrimidine sodium or 4 parts, SDM sodium, oligofructose 5 parts, anhydrous glucose 35 parts, Maifanitum 20 parts, Radix Bupleuri 7 parts, 7 parts, Poria, pine needle powder 5 parts.
A preparation method for the pharmaceutical preparation of novel control swine toxoplasmosis, comprises the following steps:
Step one, takes Maifanitum, Radix Bupleuri, Poria, pine needle powder, micronizing, crosses 150 mesh sieves, makes pharmaceutical carrier;
Step 2, takes doxycycline hydrochloride, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole, trimethoxy pyrimidine sodium or SDM sodium, oligofructose, abundant mix homogeneously;
Step 3, by the mixture of step one and the abundant mix homogeneously of the mixture of step 2;
Step 4, takes anhydrous glucose, stirs, obtain pharmaceutical preparation of the present invention together with step 3 gained mixture.
Embodiment six
A kind of pharmaceutical preparation of novel control swine toxoplasmosis, formulated by weight by following compatibility: doxycycline hydrochloride 10 parts, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole 10 parts, trimethoxy pyrimidine sodium or 2 parts, SDM sodium, oligofructose 3 parts, anhydrous glucose 40 parts, Maifanitum 20 parts, Radix Bupleuri 6 parts, 8 parts, Poria, pine needle powder 8 parts.
A preparation method for the pharmaceutical preparation of novel control swine toxoplasmosis, comprises the following steps:
Step one, takes Maifanitum, Radix Bupleuri, Poria, pine needle powder, micronizing, crosses 150 mesh sieves, makes pharmaceutical carrier;
Step 2, takes doxycycline hydrochloride, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole, trimethoxy pyrimidine sodium or SDM sodium, oligofructose, abundant mix homogeneously;
Step 3, by the mixture of step one and the abundant mix homogeneously of the mixture of step 2;
Step 4, takes anhydrous glucose, stirs, obtain pharmaceutical preparation of the present invention together with step 3 gained mixture.
Be below the application example of pharmaceutical preparation of the present invention:
One, application example 1
Scale pig farm, Period In Maoming city, in July, 2014, there is loss of appetite in 300 bull growing and fattening pigs, part pig dyspnea, and in ventral breathing, with cough, body temperature is many at 40 DEG C ~ 41.5 DEG C, delays and does not move back.There are ecchymosis in part pig lower body part and ear.Through the laboratory diagnosis of Maoming City Disease Control and Prevention Center, be diagnosed as swine toxoplasmosis.
Select disease pig 240, be divided into 8 groups at random, be respectively test A, B, C, D, E, F, drug control group, blank group, often organize 30.Wherein, the preparation of the A group mixed feeding embodiment of the present invention one is tested; The preparation of the test B group mixed feeding embodiment of the present invention two; The preparation of the test C group mixed feeding embodiment of the present invention three, the preparation of the test D group mixed feeding embodiment of the present invention four, the preparation of the test E group mixed feeding embodiment of the present invention five, the preparation of the test F group mixed feeding embodiment of the present invention six, drug control group mixed feeding doxycycline hydrochloride+compound sulfonamide pregnancy preparation, often organize and all add corresponding medicine 1kg/ ton feedstuff, feed continuously 5; Blank group does not add any medicine.
Observe in seven days and the Clinical symptoms of recording laboratory animal, judge therapeutic effect.
Index of assessment of curative effect
Cure rate: clinical symptoms disappears completely after medication treatment, spirit and diet recover normal for curing.
Effective percentage: the animal of curing after medication treatment and symptom have and obviously alleviate, and are judged to be effectively.
Inefficiency: through medication treatment after clinical symptoms do not disappear, the state of an illness do not take a turn for the better and treatments period because of being judged to of primary disease death invalid.
Clinical test results is in table 1
Table 1 pharmaceutical preparation of the present invention is to the therapeutic effect of swine toxoplasmosis
| Group | A group | B group | C group | D group | E group | F group | Drug control group | Matched group |
| Case load | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Cure rate % | 80.00% | 83.33% | 86.67% | 93.33% | 100% | 100% | 50% | 0% |
| Effective percentage % | 86.67% | 90.00% | 93.34% | 96.66% | 100% | 100% | 60% | 10.00% |
| Inefficiency % | 13.33% | 10.00% | 6.66% | 3.34% | 0% | 0% | 40% | 90.00% |
As shown in Table 1, pharmaceutical preparation of the present invention, compared with doxycycline hydrochloride+compound sulfonamide pregnancy hybrid medicine preparation, has significant curative effect to treatment swine toxoplasmosis; And after curing, appetite and speed of weight increment recover all very fast.Consider from preparation cost, embodiment six is best of breed of the present invention.
Two, the experiment of invention formulation prevention swine toxoplasmosis
Select the scale pig farm having toxoplasma to exist through test in laboratory, use invention formulation embodiment six, select the piglets 90 that age in days is close, be divided into 3 groups at random, be respectively A group, drug control group, matched group, often organize 30.Wherein, the preparation of the test A group mixed feeding embodiment of the present invention six, drug control group mixed feeding doxycycline hydrochloride+compound sulfonamide pregnancy pharmaceutical preparation, often organize and all add corresponding medicine 1kg/ ton feedstuff, feed continuously 5, matched group does not add any medicine, selects 30 toxoplasmas else and is detected as feminine gender and makes normal healthy controls group.Result of the test is as table 2.
Table 2 pharmaceutical preparation of the present invention is to the preventive effect of swine toxoplasmosis
| Group | A group | Drug control group | Matched group | Normal healthy controls group |
| Test pig number | 30 | 30 | 30 | 30 |
| Morbidity number | 0 | 12 | 25 | 0 |
| Sickness rate % | 0% | 40% | 83.33% | 0% |
From table 1, table 2, pharmaceutical preparation of the present invention, compared with doxycycline hydrochloride+compound sulfonamide pregnancy medicament mixed preparation, has significant curative effect to control swine toxoplasmosis, regularly uses the sickness rate that significantly can reduce pig farm toxoplasmosis, significantly improve benefit of raising pigs, be worthy of popularization.
Claims (2)
1. prevent and treat the pharmaceutical preparation of swine toxoplasmosis for one kind, it is characterized in that: formulated by weight by following compatibility: doxycycline hydrochloride 8-20 part, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole 10-20 part, trimethoxy pyrimidine sodium or SDM sodium 1-4 part, oligofructose 3-6 part, anhydrous glucose 20-40 part, Maifanitum 20-30 part, Radix Bupleuri 5-10 part, Poria 4-10 part, pine needle powder 5-10 part.
2. a kind of pharmaceutical preparation preventing and treating swine toxoplasmosis as claimed in claim 1, is characterized in that preparation method comprises the following steps:
Step one, takes Maifanitum, Radix Bupleuri, Poria, pine needle powder, micronizing, crosses 150 mesh sieves, makes pharmaceutical carrier;
Step 2, takes doxycycline hydrochloride, sulfobutyl ether-β-cyclodextrin sodium or sulfamethoxazole, trimethoxy pyrimidine sodium or SDM sodium, oligofructose, abundant mix homogeneously;
Step 3, by the mixture of step one and the abundant mix homogeneously of the mixture of step 2;
Step 4, takes anhydrous glucose, stirs, obtain pharmaceutical preparation together with step 3 gained mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610117167.5A CN105535051A (en) | 2016-03-02 | 2016-03-02 | Pharmaceutical preparation for preventing and treating toxoplasmosis of pigs and preparation method of pharmaceutical preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610117167.5A CN105535051A (en) | 2016-03-02 | 2016-03-02 | Pharmaceutical preparation for preventing and treating toxoplasmosis of pigs and preparation method of pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105535051A true CN105535051A (en) | 2016-05-04 |
Family
ID=55814976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610117167.5A Pending CN105535051A (en) | 2016-03-02 | 2016-03-02 | Pharmaceutical preparation for preventing and treating toxoplasmosis of pigs and preparation method of pharmaceutical preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535051A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816663A (en) * | 2009-02-26 | 2010-09-01 | 河南惠通天下动物药业有限公司 | Medicinal composition and injecta for curing avian toxoplasmosis, and preparation method thereof |
| CN102727693A (en) * | 2012-06-20 | 2012-10-17 | 青岛绿曼生物工程有限公司 | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof |
| CN104431347A (en) * | 2014-09-30 | 2015-03-25 | 全椒县大地种植专业合作社 | Feed additive for preventing and treating swine toxoplasmosis |
-
2016
- 2016-03-02 CN CN201610117167.5A patent/CN105535051A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816663A (en) * | 2009-02-26 | 2010-09-01 | 河南惠通天下动物药业有限公司 | Medicinal composition and injecta for curing avian toxoplasmosis, and preparation method thereof |
| CN102727693A (en) * | 2012-06-20 | 2012-10-17 | 青岛绿曼生物工程有限公司 | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof |
| CN104431347A (en) * | 2014-09-30 | 2015-03-25 | 全椒县大地种植专业合作社 | Feed additive for preventing and treating swine toxoplasmosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893272B (en) | A kind of pharmaceutical composition and preparation method for the treatment of livestock dysentery | |
| US20160143321A1 (en) | Feed additive for swine and feed composition containing the same | |
| CN102302599A (en) | Chinese medicinal composition for preventing and treating porcine diarrhea | |
| CN103006792A (en) | Veterinary drug for preventing livestock bowel diseases, preparation method of drug, and feed | |
| EA017656B1 (en) | Composition for prevention and treatment of pig dysentery | |
| CN103006916A (en) | Pure traditional Chinese medicine recipe for curing various animal diarrhoeal diseases and preparation method of pure traditional Chinese medicine recipe | |
| CN103006758A (en) | Chinese medicament composition for treating infectious bursal disease and preparation method thereof | |
| CN101417018B (en) | Preparation method of animal injection capable of clearing away the heat-evil and expelling superficial evils, cooling blood and relieving dysentery | |
| CN102716214B (en) | Veterinary medicine composition for preventing and treating mycotoxin pathopoiesia | |
| CN105535051A (en) | Pharmaceutical preparation for preventing and treating toxoplasmosis of pigs and preparation method of pharmaceutical preparation | |
| CN104189167B (en) | A kind of treat cataplasma of piglet diarrhea and preparation method thereof | |
| CN102961563B (en) | Pharmaceutical composition for treating livestock and poultry dysentery and preparation method thereof | |
| CN101966201A (en) | Compound norfloxacin nicotinic soluble powder and preparation method thereof | |
| CN104000895B (en) | A kind of Chinese medicine extract of alternative antibiotic and preparation method and application | |
| CN103585313A (en) | Compound Chinese-western powder for treating fish disease | |
| CN103203004B (en) | Medicinal composition with dysentery stopping effect and preparation method thereof | |
| CN108186750A (en) | A kind of Chinese medicine composition for preventing grice diarrhoea and its preparation method and application | |
| CN103520699B (en) | A kind of veterinary traditional Chinese medicine antiviral injection and preparation method thereof | |
| CN105560446A (en) | Medicinal preparation for preventing and curing mycoplasmosis of livestock and improving non-specific immunity and preparing method of medicinal preparation | |
| CN101264098A (en) | Medicinal composition for preventing and controlling livestock and fowls from infection disease | |
| CN103316037A (en) | Mineral immunizing booster for treating swine diarrhea and improving swine production performance | |
| CN106213003A (en) | Clear feed additive of fowl plague poison and its preparation method and application | |
| CN101264109A (en) | Medicinal composition for preventing and controlling pig diarrhea | |
| CN104645311A (en) | Drinking agent for treating intestinal infection of livestock and poultry and preparation method of drinking agent | |
| CN106890212B (en) | Application of acanthopanax and astragalus traditional Chinese medicine composition in preventing and treating porcine respiratory disease syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160504 |